Open AccessPatient Preferences for Rituximab Additional Risk Minimization Measures
Author(s) -
Kristyna Schneiderova,
Nathalie Bere,
Doris I. Stenver,
Sabine M. J. M. Straus
Publication year - 2021
Publication title -
journal of patient safety
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.546
H-Index - 34
eISSN - 1549-8425
pISSN - 1549-8417
DOI - 10.1097/pts.0000000000000919
Subject(s) - rituximab , medline , minification , medicine , risk analysis (engineering) , computer science , chemistry , world wide web , lymphoma , biochemistry
Patients' opinions are essential in optimizing risk minimization measures (RMMs) because they bring their real-life experience of disease management and medicines' use into the regulatory assessments. The aim of the survey launched in 2018 by the European Medicines Agency, in collaboration with the Pharmacovigilance Risk Assessment Committee, was to consult targeted patient groups treated with rituximab for nononcology indications to evaluate their preferences on how to receive information on progressive multifocal leukoencephalopathy and (serious) infections. Additional RMMs such as educational materials for physicians and patients including a patient alert card (PAC) and a patient brochure (PB) are in place to minimize these risks.